Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII

Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at
Chemotherapy Foundation Symposium XXII 


WESTMINSTER, Colo., Nov. 11  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) today announced that there will be a presentation on the
Company's lead clinical candidate, EFAPROXYN(TM) (efaproxiral) at the Twenty
Second Annual Chemotherapy Foundation Symposium taking place November 10-13 at
the Marriott Marquis Hotel in New York City.  John H. Suh, M.D., Director,
Gamma Knife Center, Clinical Director, Radiation Oncology, Brain Tumor
Institute at the Cleveland Clinic Foundation will give an oral presentation
titled "Efaproxiral (RSR13) as an Adjunct to Whole Brain Radiation Therapy for
Patients with Brain Metastases" on Friday, November 12, 2004, at 1:40 PM ET.

About EFAPROXYN

EFAPROXYN is the first synthetic small molecule designed to "sensitize" hypoxic
(oxygen-deprived) areas of tumors during radiation therapy by facilitating the
release of oxygen from hemoglobin, the oxygen-carrying protein contained within
red blood cells, and increasing the level of oxygen in tumors.  The presence of
oxygen in tumors is an essential element for the effectiveness of radiation
therapy in the treatment of cancer.  By increasing tumor oxygenation at the
time of treatment, EFAPROXYN has the potential to enhance the efficacy of
standard radiation therapy.  Unlike chemotherapeutics or other radiation
sensitizers, EFAPROXYN does not have to cross the blood brain barrier or enter
the tumor to be effective.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, EFAPROXYN, is a synthetic small molecule
that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and
enhance the efficacy of standard radiation therapy.  In addition, Allos is
developing PDX (pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) that is currently being investigated in patients
with non-small cell lung cancer and non-Hodgkin's lymphoma.  For more
information, please visit the company's web site at: http://www.allos.com/.

Safe Harbor Statement

This announcement contains forward-looking statements that involve risks and
uncertainties.  Future events may differ materially from those discussed herein
due to a number of factors, including, but not limited to, risks and
uncertainties detailed from time to time in the Company's SEC filings,
including its Annual Report on Form 10-K, as amended, for the year ended
December 31, 2003.  The Company's product candidates are in various stages of
development and may never be fully developed in a manner suitable for
commercialization.  If the company does not develop commercially successful
products, its ability to generate revenue will be limited.  If the Company is
unable to raise additional capital when required or on acceptable terms, it may
have to significantly delay, scale back or discontinue one or more of its drug
development programs.  Delays in clinical trials, whether caused by adverse
events, patient enrollment rates, regulatory issues or other factors, could
adversely affect the Company's financial position and prospects. Results from
earlier clinical trials are not necessarily predictive of future clinical
results.  If the Company is unable to generate meaningful amounts of revenue or
cannot otherwise raise the necessary funds to support operations, it may not be
able to continue as a going concern.  The Company cautions investors not to
place undue reliance on the forward looking statements contained in this press
release.  All forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company assumes no
responsibility to update such statements. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman, Manager, Corporate Communications of Allos

Therapeutics, Inc., [phone], 



Web site:  http://www.allos.com/ 

Copyright